\-\ Texto\\:\\ \ \(0\)\
\-\ axial\\ contrast\\-enhanced\\ ct\\ images\\ reveal\\ a\\ large\\,\\ mildly\\ heterogeneous\\,\\ enhancing\\ right\\ hilar\\ mass\\ that\\ measures\\ 7\\.2cm\\ ap\\.\\ \\ no\\ distinct\\ calcification\\ or\\ necrosis\\ is\\ appreciated\\,\\ no\\ other\\ masses\\ or\\ nodules\\ are\\ appreciated\\.\\ the\\ mass\\ exerts\\ minimal\\ compressive\\ effect\\ on\\ the\\ superior\\ vena\\ cava\\ and\\ right\\ atrium\\.\ \(0\)\
\-\ castleman\\ disease\ \(0\)\
\-\ broad\\ differential\\ for\\ asymmetric\\ hilar\\ lymphadenopathy\\ includes\\ infection\\ \\(tuberculosis\\ or\\ other\\ granulomatous\\/infectious\\ causes\\)\\,\\ primary\\ or\\ metastatic\\ lung\\ cancer\\,\\ metastatic\\ disease\\,\\ lymphoma\\,\\ sarcoidosis\\,\\ inflammatory\\ pneumoconioses\\,\\ collagen\\ vascular\\ disease\\,\\ reactive\\ hyperplasia\ \(0\)\
\-\ 50yo\\ man\\ presents\\ for\\ follow\\-up\\ of\\ his\\ \\"castleman\\ disease\\,\\ hyaline\\ vascular\\ variant\\"\\.\\ \\ no\\ prior\\ studies\\ are\\ available\\.\ \(0\)\
\-\ if\\ the\\ mass\\ continues\\ to\\ grow\\,\\ it\\ could\\ compress\\ the\\ right\\ atrium\\/svc\\ and\\ result\\ in\\ superior\\ vena\\ cava\\ syndrome\\,\\ so\\ continued\\ monitoring\\ was\\ recommended\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ castleman\\:\\ 0\\.27235772015158544\ \(0\)\
\-\ atrium\\:\\ 0\\.21974680800717314\ \(0\)\
\-\ vena\\:\\ 0\\.20916942506310462\ \(0\)\
\-\ cava\\:\\ 0\\.2081573450578512\ \(0\)\
\-\ hilar\\:\\ 0\\.19850896857030742\ \(0\)\
\-\ appreciated\\:\\ 0\\.19517456413206627\ \(0\)\
\-\ disease\\:\\ 0\\.18174533422942196\ \(0\)\
\-\ 50yo\\:\\ 0\\.16540938318312762\ \(0\)\
\-\ or\\:\\ 0\\.15062247845780086\ \(0\)\
\-\ pneumoconioses\\:\\ 0\\.14933158811189579\ \(0\)\
\-\ exerts\\:\\ 0\\.14679777979422556\ \(0\)\
\-\ vascular\\:\\ 0\\.14291999968584784\ \(0\)\
\-\ superior\\:\\ 0\\.14074582269636085\ \(0\)\
\-\ hyaline\\:\\ 0\\.1336450517581225\ \(0\)\
\-\ compress\\:\\ 0\\.13038412860113172\ \(0\)\
\-\ mass\\:\\ 0\\.12403717463452199\ \(0\)\
\-\ grow\\:\\ 0\\.12371622174431324\ \(0\)\
\-\ metastatic\\:\\ 0\\.11873113395952466\ \(0\)\
\-\ compressive\\:\\ 0\\.1177374405676554\ \(0\)\
\-\ distinct\\:\\ 0\\.11488577933204655\ \(0\)\
\-\ other\\:\\ 0\\.112424080228655\ \(0\)\
\-\ collagen\\:\\ 0\\.10987340400358657\ \(0\)\
\-\ monitoring\\:\\ 0\\.10794203915844787\ \(0\)\
\-\ right\\:\\ 0\\.10766054857612511\ \(0\)\
\-\ no\\:\\ 0\\.10559763549448391\ \(0\)\
\-\ continues\\:\\ 0\\.10334405012253901\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.09868231906304185\ \(0\)\
\-\ broad\\:\\ 0\\.09776545591513007\ \(0\)\
\-\ asymmetric\\:\\ 0\\.09741076567210709\ \(0\)\
\-\ variant\\:\\ 0\\.09605480499685831\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.09525403742367036\ \(0\)\
\-\ reactive\\:\\ 0\\.09289747832382078\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.09169015685229118\ \(0\)\
\-\ reveal\\:\\ 0\\.09105119495095249\ \(0\)\
\-\ so\\:\\ 0\\.09105119495095249\ \(0\)\
\-\ continued\\:\\ 0\\.08869096716231735\ \(0\)\
\-\ measures\\:\\ 0\\.08825221060901497\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.087507982849089\ \(0\)\
\-\ mildly\\:\\ 0\\.08740400792860094\ \(0\)\
\-\ the\\:\\ 0\\.08639316055636038\ \(0\)\
\-\ recommended\\:\\ 0\\.08610175624905063\ \(0\)\
\-\ nodules\\:\\ 0\\.08600518924414048\ \(0\)\
\-\ includes\\:\\ 0\\.08417039140391193\ \(0\)\
\-\ necrosis\\:\\ 0\\.08273919720091365\ \(0\)\
\-\ minimal\\:\\ 0\\.08257770366860029\ \(0\)\
\-\ are\\:\\ 0\\.08214617096461242\ \(0\)\
\-\ causes\\:\\ 0\\.08179023069100404\ \(0\)\
\-\ result\\:\\ 0\\.08103413961371023\ \(0\)\
\-\ studies\\:\\ 0\\.07940160575573656\ \(0\)\
\-\ could\\:\\ 0\\.07873338968524905\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.07834347098936602\ \(0\)\
\-\ ap\\:\\ 0\\.07771089989656772\ \(0\)\
\-\ calcification\\:\\ 0\\.0772803218481147\ \(0\)\
\-\ effect\\:\\ 0\\.07593065378625864\ \(0\)\
\-\ masses\\:\\ 0\\.07368938384236078\ \(0\)\
\-\ available\\:\\ 0\\.07343937527835027\ \(0\)\
\-\ inflammatory\\:\\ 0\\.07319261789323217\ \(0\)\
\-\ cancer\\:\\ 0\\.07209712265897082\ \(0\)\
\-\ differential\\:\\ 0\\.07033069692473652\ \(0\)\
\-\ enhancing\\:\\ 0\\.06780743341173437\ \(0\)\
\-\ primary\\:\\ 0\\.06655742720919375\ \(0\)\
\-\ lung\\:\\ 0\\.06584513109418107\ \(0\)\
\-\ his\\:\\ 0\\.06564643424710198\ \(0\)\
\-\ for\\:\\ 0\\.0656149094127693\ \(0\)\
\-\ infection\\:\\ 0\\.06538470078008504\ \(0\)\
\-\ syndrome\\:\\ 0\\.06525517552964345\ \(0\)\
\-\ lymphoma\\:\\ 0\\.06446507907107249\ \(0\)\
\-\ if\\:\\ 0\\.06289155109273795\ \(0\)\
\-\ axial\\:\\ 0\\.06252472943662445\ \(0\)\
\-\ prior\\:\\ 0\\.06056183879006256\ \(0\)\
\-\ man\\:\\ 0\\.057304894950589116\ \(0\)\
\-\ it\\:\\ 0\\.05540779530222189\ \(0\)\
\-\ large\\:\\ 0\\.05423483866745545\ \(0\)\
\-\ presents\\:\\ 0\\.052070203857044806\ \(0\)\
\-\ images\\:\\ 0\\.050069337763820713\ \(0\)\
\-\ that\\:\\ 0\\.04697316237521872\ \(0\)\
\-\ and\\:\\ 0\\.04473395258503438\ \(0\)\
\-\ ct\\:\\ 0\\.04120891552194087\ \(0\)\
\-\ was\\:\\ 0\\.03772356413884714\ \(0\)\
\-\ on\\:\\ 0\\.032691076693556\ \(0\)\
\-\ is\\:\\ 0\\.029642929282136396\ \(0\)\
\-\ to\\:\\ 0\\.027060398920458154\ \(0\)\
\-\ in\\:\\ 0\\.026927207693015667\ \(0\)\
\-\ of\\:\\ 0\\.02118256761055557\ \(0\)\
